Cancer chemoresistance: The relationship between p53 and multidrug transporters

International Journal of Cancer

Volumn 98, Issue 3, 2002, Pages 323-330

  Bush, Jason A ^a   Li, Gang ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b JACK BELL RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BILE SALT; CAMPTOTHECIN DERIVATIVE; COLCHICINE; DAUNORUBICIN; DIGOXIN; DOXORUBICIN; DYE; ETOPOSIDE; GLUTATHIONE; MESSENGER RNA; METHOTREXATE; MITOXANTRONE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PACLITAXEL; PHOSPHATIDYLCHOLINE; PROTEIN BCL 2; PROTEIN P53; RHODAMINE; STEROID; SULFINPYRAZONE; VINBLASTINE; VINCRISTINE;

ANIMAL CELL; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CHEMOSENSITIVITY; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

APOPTOSIS; DRUG RESISTANCE, NEOPLASM; GENES, P53; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS;

EID: 0037139396     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10226     Document Type: Short Survey

References (113)

1. Cellular mechanisms of multidrug resistance of tumor cells
2. Multidrug resistance (Mdr) in cancer. Mechanisms, reversal using modulators of Mdr and the role of Mdr modulators in influencing the pharmacokinetics of anticancer drugs
3. Modulation of activity of the promoter of the human Mdr1 gene by Ras and p53
4. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53
5. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells
6. Cloning and initial analysis of the human multidrug resistance-related MVP/LRP gene promoter
7. The human ATP-binding cassette (ABC) transporter superfamily
8. Multidrug resistance transporters and modulation
9. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
10. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells
11. Structural and functional characterization of the mouse multidrug resistance gene family
12. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance
13. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein
14. The human multidrug resistance-associated protein (MRP) gene family: From biological function to drug molecular design
15. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily
16. A multidrug resistance transporter from human MCF-7 breast cancer cells
17. Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2
18. The drag resistance-related protein LRP is the human major vault protein
19. Isolation and characterization of a novel ribonucleoprotein particle: Large structures contain a single species of small RNA
20. Lung resistance related protein/major vault protein and vaults in multidrug-resistant cancer
21. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene
22. Identification of 5′ and 3′ sequences involved in the regulation of transcription of the human mdr1 gene in vivo
23. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant p53 proteins
24. Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drags
25. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance
26. Characterization of the promoter region of the human MDR3 P-glycoprotein gene
27. Human bile salt export pump promoter is transactivated by the Farnesoid X Receptor/Bile Acid Receptor
28. Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin
29. The human multidrug resistance protein 2 gene: Functional characterization of the 5′-flanking region and expression in hepatic cells
30. Characterization of the 5′-flanking region of the human multidrug resistance protein 2 (MRP2) gene and its regulation in comparison with the multidrug resistance protein 3 (MRP3) gene
31. Characterization of 5′-flanking region of human MRP3
32. Twenty years of p53 research: Structural and functional aspects of the p53 protein
33. The p53 tumor suppressor gene: From molecular biology to clinical investigation
34. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome
35. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays
36. DNA microarray analysis of genes involved in p53 mediated apoptosis: Activation of Apaf-1
37. Definition of a consensus binding site for p53
38. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia
39. The p53-mdm-2 autoregulatory feedback loop
40. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
41. Tumor suppressor p53 is a regulator of bc1-2 and bax gene expression in vitro and in vivo
42. Noxa, a BH3-only member of the Bc1-2 family and candidate mediator of p53-induced apoptosis
43. PUMA, a novel proapoptotic gene, is induced by p53
44. Apaf-1 is a transcriptional target for E2F and p53
45. p53 activates the CD95 (APO 1/Fas) gene in response to DNA damage by anticancer drags
46. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis
47. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants
48. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53
49. Mutant p53 cooperates with ETS and selectively upregulates human MDR1 not MRP1
50. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts
51. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line
52. Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts
53. Aromatic hydrocarbon receptor (AhR). AhR nuclear translocator- and p53-mediated induction of the murine multidrug resistance mdr1 gene by 3-methylcholanthrene and benzo(a)pyrene in hepatoma cells
54. Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drag daunombicin
55. Wild-type p53 marginally induces endogenous Mdr-1 mRNA without causing a measurable drug resistance in human cancer cells
56. Wild-type p53 gene increases MDR1 gene expression but decreases drag resistance in an MDR cell line KBV200
57. p53 mutational spectra and the role of methylated CpG sequences
58. Gain of function mutations in p53
59. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants
60. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain
61. p53 mutants without a functional tetramerisation domain are not oncogenic
62. Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties
63. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53
64. Transcriptional repression by p53 through direct binding to a novel DNA element
65. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents
66. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
67. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent
68. p53-dependent apoptosis in melanoma cells after treatment with camptothecin
69. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance
70. Differential sensitivities of the MRP gene family and gamma-glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status
71. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer
72. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy
73. p53 but not bc1-2 immuno-staining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients
74. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: Correlation to messenger RNA expression and to immunohistochemical prognostic indicators
75. Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein
76. Immunocytochemical detection of the p170 multidrug resistance (Mdr) and the p53 tumor suppressor gene proteins in human breast cancer cells: Clinical and therapeutical significance
77. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy
78. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
79. Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients
80. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: Correlation with the response to therapy and the expression of MDR1 and LRP
81. The coexpression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma
82. Multidrug resistance related genes and p53 expression in human non small cell lung cancer
83. MDRi expression correlates with mutant p53 expression in colorectal cancer metastases
84. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo
85. P-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosis
86. MDR1 gene expression in chronic lymphocytic leukemia
87. Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes
88. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression
89. Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes
90. MBR rearrangement and P-glycoprotein expression are not independent prognostic factors like p53 protein in malignant lymphoma
91. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma
92. Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squamous cell carcinoma
93. Pharmacodynamics of taxol in human head and neck tumors
94. Expression of P-glycoprotein in hepatocellular carcinoma: A potential marker of prognosis
95. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: Clinical correlation
96. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response
97. Correlation of MDR1 expression and oncogenic activation in human epithelial ovarian carcinoma
98. The expression of drug resistance gene products during the progression of human prostate cancer
99. Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer
100. Drug resistance and sensitivity of germ cell testicular tumors: Evaluation of clinical relevance of MDR1/Pgp, p53, and metallothionein (MT) proteins
101. Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer
102. Differential expression of the multidrug resistance-related protein MRP1 in the histological compartments of nephroblastomas
103. Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer
104. MRP expression of testicular cancers and its clinical relevance
105. Multidrug resistance-associated protein expression in clinical gastric carcinoma
106. Drug resistance studies using fresh human ovarian carcinoma and soft tissue sarcoma samples
107. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas
108. Mdrlb facilitates p53-mediated cell death and p53 is required for Mdr1b upregulation in vivo
109. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity
110. bc1-2 antisense therapy chemosensitizes human melanoma in SCID mice
111. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer
112. Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts
113. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma